An Open-Label, Multi-center Phase I/II Dose Escalation and Expansion Study to Assess the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Latest Information Update: 06 Mar 2024
At a glance
- Drugs MRG 002 (Primary)
- Indications Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Miracogen
- 01 Sep 2021 Planned number of patients changed from 152 to 129.
- 03 Aug 2020 New trial record